Breaking News
Thomas Muster
About Thomas Muster
PhD in Biotechnology and Associate Professor for Virology. Positions as Research Fellow at the Mount Sinai School of Medicine in New York, Staff Investigator of the Virology Group at the Institute of Applied Microbiology at the University of Applied Life Sciences and at the Department of Dermatology at the Medical University in Vienna. Founder and CEO of AVIR Green Hills Biotechnology and BlueSky Immunotherapies. Currently CEO of BlueSky Immunotherapies and CSO of Vivaldi Biosciences. More than 20 key inventions in vaccine development such as the discovery of a conserved antigen on HIV, a melanoma-associated retrovirus, and the interferon antagonist NS1 of influenza virus. Co-authored more than fifty publications in the fields of virology and oncology. Successfully steered the development of the live attenuated influenza vaccine deltaFLU and the cancer immunotherapy candidate delNS/E6E7 from discovery into clinical trials.